Questcor resubmits filing for Acthar gel in infantile spasms
This article was originally published in Scrip
Executive Summary
Questcor Pharmaceuticals has reformatted its US supplemental NDA for its long-acting injectable corticotrophin formulation, Acthar gel, for the treatment of infantile spasms (IS), a rare form of refractory childhood epilepsy.